Share this Post!

The Food and Drug Administration (FDA) advises the public against the purchase and use of the following unregistered drug products:

  1. OTC QING HUO PIAN
  2. MIAOYAO JIAOQIWANG SHADUKANG PENJI
  3. JIANGXI MINJI XIAN ZHU LI
  4. OTC FANGFENG TONGSHENG WAN
  5. GUI ZHI FU LING WAN
  6. OTC TAIJI® SANLIETONG COMPOUND PARACETAMOL TABLETS (II)
  7. OTC FOLIC ACID TABLETS [as reflected in the Package Insert]
  8. ROXITHROMYCIN TABLETS
  9. OTC MILIAN CHUANBEI PIPA GAO
  10. NANCHANG® [Label in Foreign Language]
  11. OTC NONGSUOWAN MAIWEI DIHUANGWAN
  12. PANTUO LAZUONA CHANGRONGPIAN
  13. OTC SHENG MAI YIN (DANG SHEN FANG)
  14. QINGLIN KELI [as reflected in the Package Insert]
  15. RIBAVIRIN INJECTION
  16. OTC [Label in Foreign Language]
  17. PIDI® COLCHICINE TABLETS
  18. OTC CNWM XIONGDAN ZHILING SHUAN
  19. [Label in Foreign Language]
  20. OTC CICLOPIROX OLAMINE CREAM [as reflected in the Package Insert]
  21. OMEPRAZOLE ENTERIC CAPSULE
  22. OTC TIAOJING ZHITONG JIAONANG [as reflected in the Package Insert]
  23. NUO FU SHA XING JIAONANG
  24. DA NING TANG LIAN QIAO BAI DU PIAN
  25. OTC QINGYUAN CALCIUM GLUCONATE TABLETS
  26. BAI NIAN SAN WEI
  27. CHUZHI SHENGFA PIAN
  28. OTC ZEYSUB® [Label in Foreign Language]
  29. OTC QUAN LU WAN
  30. TIANRANCAOBENPEIFANG YIGANERJING
  31. OTC LORATADINE TABLETS
  32. OTC SUL FUR OINTMENT [as reflected in the Primary Packaging]
  33. OTC LACONCORDE NAPHAZOLINE HYDROCHLORIDE, CHLORPHENAMINE MALEATE AND VITAMIN B12 EYE DROPS (CONTAINING SODIUM HYALURONATE)
  34. OTC BUSHEN QIANGSHEN JIAONANG
  35. OTC [Label in Foreign Language]
  36. OTC [Label in Foreign Language]
  37. [Label in Foreign Language]
  38. RHINITIS SPRAY
  39. WEI A NING HERBACEOUS EXTRACTION ANTIBACTERIAL
  40. OTC SANJIN® PIAN
  41. OTC [Label in Foreign Language]
  42. [Label in Foreign Language]
  43. OTC GLYCERINE ENEMA
  44. ZJIACHMEI LANG DU JUN E JING

FDA Post-Marketing Surveillance (PMS) activities have verified that the abovementioned drug products have not gone through the registration and testing process of the Agency and have not been issued with proper authorization in the form of Certificate of Product Registration. Thus, the Agency cannot guarantee their quality and safety. The consumption of such violative products may pose potential danger or injury if administered.

Pursuant to Republic Act No. 9711, otherwise known as the “Food and Drug Administration Act of 2009”, the manufacture, importation, exportation, sale, offering for sale, distribution, transfer, promotion, advertising or sponsorship of health products without proper authorization from FDA is prohibited.

In light of the above, the public is advised not to purchase the aforementioned violative products and to be vigilant against it. Always check if a drug product has been registered with the FDA before purchasing it by making use of the embedded Search feature of the FDA website accessible at www.fda.gov.ph. You may also look for the FDA Registration number on the product label.

All concerned establishments and/or entities are warned not to distribute the above-identified violative drug products until they have already been covered by the appropriate authorization, otherwise, regulatory actions and sanctions shall be strictly pursued.

All Local Government Units (LGUs) and Law Enforcement Agencies (LEAs) are requested to ensure that these products are not sold or made available in their localities or areas of jurisdiction.

For more information and inquiries, please e-mail us at info@fda.gov.ph. To report continuous sale or distribution of unregistered health products, kindly e-mail us via report@fda.gov.ph, or through the online reporting facility, eReport, at www.fda.gov.ph/ereport. You may also call the

Center for Drug Regulation and Research at telephone number (02)809-5596. For any suspected adverse drug reaction (ADR), report immediately to FDA through this link: www.fda.gov.ph/adr-report-new and fill out all the required fields.

Dissemination of the information to all concerned is requested.

Attachment:-> FDA Advisory No. 2019-384